Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 13/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 11/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 9/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ULK1 | O75385 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7163606 | 0.84 | ENPP3 (0.35) | ENPP3ENPP1ENPP2MAPTHTT | |
| SCHEMBL5037793 | 0.83 | ENPP3 (0.39) | ENPP3ENPP1ENPP2MAPTHTT | |
| SCHEMBL7145205 | 0.82 | ENPP3 (0.36) | ENPP3ENPP1ENPP2MAPTHTT | |
| SCHEMBL5042858 | 0.82 | NPC1 (0.50) | ENPP3ENPP1ENPP2MAPTPOLB | |
| SCHEMBL7141882 | 0.80 | ENPP3 (0.36) | ENPP3ENPP1ENPP2MAPTHTT | |
| SCHEMBL7139375 | 0.79 | ENPP3 (0.37) | ENPP3ENPP1ENPP2 | |
| SCHEMBL5035960 | 0.78 | ENPP3 (0.39) | ENPP3ENPP1ENPP2MAPTHTT | |
| SCHEMBL5040705 | 0.78 | ENPP3 (0.36) | ENPP3ENPP1ENPP2MAPTHTT | |
| SCHEMBL5036486 | 0.77 | ENPP3 (0.38) | ENPP3ENPP1ENPP2MAPTHTT | |
| SCHEMBL6017758 | 0.76 | ABL1 (0.39) | ENPP3ENPP1ENPP2MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1298125-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | Aventis Pharma S.A. (FR) | 2003-04-02 | — | — | EP | disclosed |